Tenet On Road to Recovery
Skolnick has a buy recommendation and a two-year price target of $8.70 on Tenet's shares. Her firm makes a market in the company's securities.
Vital Signs Still Weak
To be clear, Tenet still looks like one sick company. By now, critics have offered a long list of problems threatening the company's survival. First and foremost, Tenet carries a huge debt burden -- approaching $4.8 billion -- and generates no positive cash flow. The company's debt-to-capital ratio, hovering in the low 70% range just a few years ago, now stands at an astounding 98%. Tenet needs to boost admissions and lower costs to regain its financial health. Yet even after investing billions of dollars in capital improvements that were intended to attract well-insured patients to its hospitals, the company has seen its volumes steadily erode over the past couple of years. Only uninsured admissions -- which lead to huge bad-debt charges -- have significantly expanded during that timeframe. Florida, once a prized hospital market, has caused exceptional pain. Weak volumes there, caused by fierce competition for a dwindling number of patients who carry insurance, have wiped out gains mustered elsewhere in the system. Tenet has nonetheless clung to Florida as a core holding in its 64-hospital chain. Now, the company must repair that market -- which ranks as its second largest -- to turn around its operations as a whole.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |














